EFFICACY OF ALIROCUMAB ACCORDING TO BACKGROUND STATIN INTENSITY AND OTHER LIPID-LOWERING THERAPY IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR HIGH CV RISK POPULATIONS: PHASE 3 SUB-GROUP ANALYSES

被引：2

作者：

Krempf, M. ^{[1
]}

Bergeron, J. ^{[2
]}

Elassal, J. ^{[3
]}

Minini, P. ^{[4
]}

Miller, K. ^{[5
]}

Kastelein, J. J. P. ^{[6
]}

机构：

[1] Hop Nord Laennec, CHU Nantes, Endocrinol & Nutr, Nantes, France

[2] CHU Quebec, Clin Malad Lipid, Quebec City, PQ, Canada

[3] Regeneron Pharmaceut, Med Affairs, New York, NY USA

[4] Sanofi, Biostat & Programming, Chilly Mazarin, France

[5] Regeneron Pharmaceut, Biostat & Data Management, New York, NY USA

[6] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands

来源：

关键词：

D O I：

10.1016/j.atherosclerosis.2015.04.087

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

EAS-0493

引用

页码：E21 / E21

页数：1